Beijing-based Yellwin Medical (悦唯医疗) has completed its Series A++ funding round, raising tens of millions of RMB in an investment led exclusively by the Beijing Healthcare Industry Investment Fund. The proceeds will accelerate two key initiatives:

1. R&D expansion for next-gen cardiac devices, including a pulsatile left ventricular assist system (LVAS) and innovative coronary artery disease (CAD) diagnostic tools.

2. Commercial scaling of approved products, such as its cardiac stabilizers, to strengthen market penetration.

This funding solidifies Yellwin’s position as a pioneer in cardiovascular surgical solutions, combining clinical expertise with cutting-edge technology.

Breakthrough Product Portfolio

Yellwin specializes in end-to-end cardiac surgical devices, with a focus on coronary artery bypass grafting (CABG) and heart failure interventions. Key innovations include:

• Cardiac Stabilizers – Minimize heart motion during CABG, improving surgical precision.

• Intraoperative Ultrasound Flow Meters – Real-time blood flow monitoring during procedures.

• Left Ventricular Assist System (LVAS) – A pulsatile-design device under development to support heart function.

• Coronary Anastomosis Assist System – Streamlines vessel connection in bypass surgeries.

The company holds 20+ national patents and has advanced three new products to registration stage:

• Next-gen cardiac stabilizers.

• Femoral artery/vein cannulas for extracorporeal circulation.

• A proprietary CAD scoring system for risk stratification.

Company Background

Founded in 2021 by a team of cardiac surgeons from Beijing Anzhen Hospital (affiliated with Capital Medical University), Yellwin merges 20+ years of clinical expertise with engineering innovation. Its solutions target unmet needs in cardiac surgery and heart failure management.

Funding Milestones:

• 2021: Angel round.

• 2023: Series A (co-led by IDG Capital and Yuanhui Chuangyi).

• 2023: Series A+ (~$14M USD) with participation from Nuoyu Capital, Zhongnan Capital, Chen Capital, and existing investors.

Yellwin will leverage the new capital to fast-track R&D and expand its commercial footprint in China’s $5B+ cardiac device market, while eyeing global regulatory pathways.

April 3, 2025, By MedChina